Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Completed · Phase 3 · NCT03112174
Conditions: Mantle-Cell Lymphoma
At a glance
- Research payments reported, 2025
- $572,165
- U.S. investigators named
- 7
- Sites paid
- 8
- Planned or actual enrollment
- 366
About the trial
- Sponsor
- Pharmacyclics LLC. (with Janssen Research & Development, LLC)
- Tested
- Ibrutinib (drug), Venetoclax (drug), Placebo Oral tablet to match Venetoclax (drug)
- Dates
- Started 2017-06-19; completion 2024-06-27
- Results posted
- Yes
This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.
From ClinicalTrials.gov, last updated 2025-07-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $572,165 in research payments for this study in 2025 (223 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Lihua E. Budde, MD, PHD Hematology · Duarte, CA
- Dipenkumar K. Modi, M.D. Internal Medicine · Detroit, MI
- Nilanjan Ghosh, MD Medical Oncology · Charlotte, NC
- Andrew D. Zelenetz, MD Medical Oncology · New York, NY
- Ian W. Flinn, M.D. Hematology & Oncology · Nashville, TN
- Krish Patel, M.D. Hematology & Oncology · Nashville, TN
- Luhua M. Wang, M.D. Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $392,642
- Memorial Sloan Kettering Cancer Cen $60,098
- Carolinas Medical Center/behav Health, NC $39,095
- Karmanos Cancer Center, MI $26,944
- City of Hope National Medical Ctr $24,286
- Sarah Cannon Research Institute $11,875
- Tennessee Oncology PLLC $10,825
- Swedish Medical Center, WA $6,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.